ENZ Fattens Purse, SLXP, MNKD Hit Highs, QCOR's Defensive Move, VRML Delivers Questcor Pharmaceuticals Inc. (QCOR) rose as much as 36% in intraday trading on Tuesday after the company announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.
June 12, 2013 - RTT News
Questcor Pharmaceuticals Acquires Rights to Synacthen® ANAHEIM, Calif., June 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced it has acquired rights to develop Synacthen ® and Synacthen Depot in the U.S. from Novartis ...
June 11, 2013 - PR Newswire via Yahoo! Finance
Questcor Buys Potential Rival Drug Questcor gains rights to potential rival Synacthen. What it means for this volatile stock.
June 11, 2013 - The Motley Fool